Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer.
Martini G, Belli V, Napolitano S, Ciaramella V, Ciardiello D, Belli A, Izzo F, Avallone A, Selvaggi F, Menegon Tasselli F, Santaniello W, Franco R, Puig I, Ramirez L, Chicote I, Mancuso F, Caratu G, Serres X, Fasani R, Jimenez J, Ros J, Baraibar I, Mulet N, Della Corte CM, Troiani T, Vivancos A, Dienstmann R, Elez E, Palmer HG, Tabernero J, Martinelli E, Ciardiello F, Argilés G.
Martini G, et al.
ESMO Open. 2023 Jun;8(3):101198. doi: 10.1016/j.esmoop.2023.101198. Epub 2023 Apr 27.
ESMO Open. 2023.
PMID: 37119788
Free PMC article.
Patient-derived tumor organoids (PDTOs) represent an unmatched model to elucidate tumor resistance to therapy, due to their high capacity to resemble tumor characteristics. ...One patient was treated with nivolumab-second mitochondrial-derived activator of ca …
Patient-derived tumor organoids (PDTOs) represent an unmatched model to elucidate tumor resistance to therapy, due to their hi …